文章：

三环类抗抑郁药与选择性血清素再摄取抑制剂对妇科癌症风险影响的真实世界数据研究

Real-World Data on the Associations of Tricyclic Antidepressants and Selective Serotonin Reuptake Inhibitors with Gynecologic Cancer Risk

原文发布日期：10 May 2025

DOI: 10.3390/cancers17101616

类型: Article

开放获取: 是

英文摘要：

Background: While the potential anti-cancer effects of antidepressants have been investigated, limited research has been conducted incorporating age-specific analyses for individual tricyclic antidepressants (TCAs) and selective serotonin reuptake inhibitors (SSRIs). This study aims to elucidate the associations between TCAs and SSRIs with gynecologic cancers and to identify specific age groups and cancer types that may benefit from the chemopreventive effects of these medications.Methods: A case-control study comprised 97,736 female patients diagnosed with gynecologic cancers between 2002 and 2016. Each newly diagnosed case of cervical, ovarian, or uterine cancer was matched with four controls. Both cases and controls were then stratified by age to perform subgroup analyses. Associations between antidepressant use and cancer risk were evaluated using multivariable conditional logistic regression models.Results: The TCA class was significantly associated with reduced risks of cervical, ovarian, and uterine cancers, displaying adjusted odds ratios (aORs) of 0.799, 0.775, and 0.813, respectively. The SSRI class also indicated reduced risks, with aORs of 0.736, 0.638, and 0.567 for the same cancer types. Particularly noteworthy were females aged 40–64, who demonstrated the most significant associations between gynecologic cancers and using TCAs or SSRIs.Conclusions: TCAs and SSRIs are associated with reduced risks of developing cervical, ovarian, and uterine cancers. The middle-aged population may have the most significant potential for future research on drug repurposing against gynecologic cancers, and both cervical and uterine cancers are potential targets for drug repurposing involving TCAs or SSRIs.

摘要翻译： 

背景：尽管抗抑郁药物的潜在抗癌效应已被研究，但针对特定三环类抗抑郁药（TCAs）和选择性5-羟色胺再摄取抑制剂（SSRIs）的年龄分层分析仍较为有限。本研究旨在阐明TCAs和SSRIs与妇科癌症之间的关联，并识别可能从这些药物的化学预防效应中获益的特定年龄组和癌症类型。 方法：本研究采用病例对照设计，纳入2002年至2016年间诊断为妇科癌症的97,736名女性患者。每例新诊断的宫颈癌、卵巢癌或子宫癌患者均与四名对照者匹配。随后对病例组和对照组进行年龄分层以开展亚组分析。通过多变量条件逻辑回归模型评估抗抑郁药物使用与癌症风险之间的关联。 结果：TCA类药物与宫颈癌、卵巢癌和子宫癌的风险降低显著相关，调整后比值比（aOR）分别为0.799、0.775和0.813。SSRI类药物同样显示风险降低，对应三种癌症的aOR分别为0.736、0.638和0.567。特别值得注意的是，40-64岁女性群体中妇科癌症与使用TCAs或SSRIs的关联最为显著。 结论：TCAs和SSRIs与降低宫颈癌、卵巢癌和子宫癌的发病风险相关。中年人群在针对妇科癌症的药物再利用研究中可能具有最重要的潜力，且宫颈癌与子宫癌均是涉及TCAs或SSRIs药物再利用的潜在目标领域。

原文链接：

Real-World Data on the Associations of Tricyclic Antidepressants and Selective Serotonin Reuptake Inhibitors with Gynecologic Cancer Risk